Tag: STRO-002
STRO-002 Shows 33% Objective Response Rate in Patients with Advanced Ovarian...
Folate receptor alpha (FolRα) is a folate-binding protein overexpressed on ovarian and several other epithelial malignancies that can be used as a target for...
Sutro’ STRO-002 Receives FDA Fast Track Designation for Patients with Advanced...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002. The investigational drug, being developed by Sutro Biopharma, is a...
Antibody-drug Conjugates: Coming of Age
Antibody-based anti-cancer therapeutics have, over the last 30+ years garnered considerable success. Antibody-drug Conjugates (ADC) are included in this revolution of these novel, highly...
Data for Dose-Escalation Phase 1 Study of Sutro’s STRO-002 Shows Encouraging...
Data from Sutro Biopharma’s dose-escalation cohort of the Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) for patients...
First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients...
A first patient has been dosed in the dose-expansion cohort of the Phase I study with STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug...
Annual World ADC – Best New Drug Developer 2020: Sutro Biopharma’s...
From liquid biopsies to precision medicine to immunology, the field of cancer treatment has experienced significant progress during the last decade. Although according to...
Preclinical Data Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors, Resulting...
Data presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020 of Sutro Biopharma's folate receptor...
AACR 2020: Phase I Clinical Trial with STRO-002 Shows Encouraging...
Updated interim data regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer from an on-going Phase I dose-escalation phase clinical...
James Panek Joins Sutro Biopharma’s Board of Directors
James P. Panek, an independent consultant since 2011, providing technical and strategic insights to companies around the world, has joined Sutro Biopharma's Board of...
Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002...
Initial safety data of STRO-002 shows potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models were presented at the AACR-NCI-EORTC.
FRα is overexpressed...
